A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer

作者：Chen, Xiangling; Yu, Chengli; Gao, Jing; Zhu, Hongwen; Cui, Binghai; Zhang, Tao; Zhou, Yanting; Liu, Qian; He, Han; Xiao, Ruoxuan; Huang, Ruimin; Xie, Hua; Gao, Daming; Zhou, Hu^*

来源：Theranostics, 2018, 8(9): 2348-2360.

DOI：10.7150/thno.22901

• non-small cell lung cancer (NSCLC)
• quantitative proteomics
• deubiquitinase
• USP9X
• TTK

The X-linked deubiquitinase, USP9X, is implicated in multiple cancers by targeting various substrates. Increased expression of USP9X is observed in non-small-cell lung cancer (NSCLC) and is correlated with poor prognosis. However, the molecular mechanism for USP9X regulation of tumor cell survival and tumorigenesis in NSCLC is less defined.
Methods: In this study, chemical labeling, quantitative proteomic screening was applied to analyze A549 cells with or without USP9X RNA interference. Functional in vitro and in vivo experiments were performed to confirm the oncogenic effects of USP9X in NSCLC and to investigate the underlying mechanisms.
Results: The resulting data suggested that dual specificity protein kinase TTK is a potential substrate of USP9X. Further experimental evidences confirmed that USP9X stabilized TTK via direct interaction and efficient deubiquitination of TTK on K48 ubiquitin chain. Moreover, knockdown of USP9X or TTK inhibited cell proliferation, migration and tumorigenesis, and the immunohistochemical analysis of clinical NSCLC samples showed that the protein expression levels of USP9X and TTK were significantly elevated and positively correlated in tumor tissues.
Conclusions: In summary, our data demonstrated that the USP9X-TTK axis may play a critical role in NSCLC, and could be considered as a potential therapeutic target.

• 出版日期2018
• 单位中国科学院上海药物研究所; 中国科学院上海生命科学研究院; 新药研究国家重点实验室; 中国科学院大学